<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616562</url>
  </required_header>
  <id_info>
    <org_study_id>NN8640-4172</org_study_id>
    <secondary_id>2015-000531-32</secondary_id>
    <secondary_id>U1111-1166-7062</secondary_id>
    <nct_id>NCT02616562</nct_id>
  </id_info>
  <brief_title>Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency</brief_title>
  <official_title>A Trial Investigating Efficacy and Safety of Once-weekly NNC0195-0092 (Somapacitan) Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency naïve Pre-pubertal Children With Growth Hormone Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted globally. The aim of the trial is to investigate efficacy and safety
      of once-weekly NNC0195-0092 (somapacitan) treatment compared to daily growth hormone
      treatment (Norditropin® FlexPro®) in growth hormone treatment naïve pre-pubertal children
      with growth hormone deficiency.

      The trial consists of a 26 week main trial period, followed by a 26 week extension trial
      period, a 104 week safety extension period, a 208 week longterm safety extension trial period
      and a 30 day follow up period. Participants receive NNC0195-0092 (somapacitan) (0.04
      mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092
      (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety
      extension periods. Two additional age groups, cohort II (age below 2 years and 26 weeks at
      screening) and cohort III (above 9 years (girls)/ above 10 years (boys) and equal to or below
      17 years at screening) are included in the 208 week long-term safety extension trial period
      only.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2016</start_date>
  <completion_date type="Anticipated">August 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 21, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Sponsor staff involved in the clinical trial is masked according to company standard procedures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cohort I: Height velocity (HV) during the first 26 weeks of treatment, measured as standing height with stadiometer</measure>
    <time_frame>Week 0-26</time_frame>
    <description>cm/year</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort II and III: Incidence of adverse events, including injection site reactions, in children with GHD</measure>
    <time_frame>During 208 weeks</time_frame>
    <description>Number of events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in height standard deviation score (SDS)</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Typically -10 to +10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height standard deviation score (SDS)</measure>
    <time_frame>Week 0-52</time_frame>
    <description>Typically -10 to +10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in height standard deviation score (SDS)</measure>
    <time_frame>Week 26-52</time_frame>
    <description>Typically -10 to +10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HV (height velocity) SDS</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Typically -10 to +10. Baseline (week 0) HV SDS is derived from reported pre-trial standing height measured at minimum 6 months and maximum 18 months prior to screening visit to standing height at baseline (week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HV (height velocity) SDS</measure>
    <time_frame>Week 0-52</time_frame>
    <description>Baseline (week 0) HV SDS is derived from reported pre-trial standing height measured at minimum 6 months and maximum 18 months prior to screening visit to standing height at baseline (week 0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like growth factor 1 (IGF-I) SDS</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Typically -10 to +10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like growth factor 1 (IGF-I) SDS</measure>
    <time_frame>Week 0-52</time_frame>
    <description>Typically -10 to +10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like growth factor 1 (IGF-I) SDS</measure>
    <time_frame>Week 26-52</time_frame>
    <description>Typically -10 to +10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like growth factor binding protein 3 (IGFBP-3) SDS</measure>
    <time_frame>Week 0-26</time_frame>
    <description>Typically -10 to +10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like growth factor binding protein 3 (IGFBP-3) SDS</measure>
    <time_frame>Week 0-52</time_frame>
    <description>Typically -10 to +10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin-like growth factor binding protein 3 (IGFBP-3) SDS</measure>
    <time_frame>Week 26-52</time_frame>
    <description>Typically -10 to +10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Height velocity</measure>
    <time_frame>Week 52</time_frame>
    <description>cm/year, derived from standing height from baseline (week 0) to week 52</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone age</measure>
    <time_frame>Week 52</time_frame>
    <description>X-Ray of left hand and wrist, central assessed according to Greulich &amp; Pyle atlas progression vs. chronological age</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum NNC0195-0092 (somapacitan) concentrations</measure>
    <time_frame>Week 52</time_frame>
    <description>ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in emotional well-being score, physical health score, social well-being score and total score in Treatment Related Impact Measure - Child Growth Hormone Deficiency- Observer (TRIM-CGHD-O)</measure>
    <time_frame>Week 0-26</time_frame>
    <description>The scores range from 0-100. A lower score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in emotional well-being score, physical health score, social well-being score and total score in Treatment Related Impact Measure - Child Growth Hormone Deficiency- Observer (TRIM-CGHD-O)</measure>
    <time_frame>Week 0-52</time_frame>
    <description>The scores range from 0-100. A lower score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score of The Treatment Burden Measure - Child Growth Hormone Deficiency - Observer (TB-CGHD-O)</measure>
    <time_frame>Week 26</time_frame>
    <description>The scores range from 0-100. A lower score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score of The Treatment Burden Measure - Child Growth Hormone Deficiency - Observer (TB-CGHD-O)</measure>
    <time_frame>Week 52</time_frame>
    <description>The scores range from 0-100. A lower score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score of The Treatment Burden Measure - Child Growth Hormone Deficiency - Parent/Guardian (TB-CGHD-P)</measure>
    <time_frame>Week 26</time_frame>
    <description>The scores range from 0-100. A lower score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total score of The Treatment Burden Measure - Child Growth Hormone Deficiency - Parent/Guardian (TB-CGHD-P)</measure>
    <time_frame>Week 52</time_frame>
    <description>The scores range from 0-100. A lower score indicates a better health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, including injection site reactions</measure>
    <time_frame>Week 364</time_frame>
    <description>Number of events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-NNC0195-0092 (somapacitan) antibodies</measure>
    <time_frame>Week 364</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of anti-hGH antibodies</measure>
    <time_frame>Week 364</time_frame>
    <description>Yes/no</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Growth Hormone Disorder</condition>
  <condition>Growth Hormone Deficiency in Children</condition>
  <arm_group>
    <arm_group_label>Blinded NNC0195-0092 (somapacitan) (0.04 mg/kg/week)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive NNC0195-0092 (somapacitan) (0.04 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded NNC0195-0092 (somapacitan) (0.08 mg/kg/week)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive NNC0195-0092 (somapacitan) (0.08 mg/kg/week) during the main trial and the extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the safety extension and the long-term safety extension periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blinded NNC0195-0092 (somapacitan) (0.16 mg/kg/week)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive the same dose (0.16 mg/kg/week) of NNC0195-0092 (somapacitan) during all 4 trial periods.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open labelled daily Norditropin® (0.034 mg/kg/day)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive Norditropin during the main trial, the extension period and the safety extension period and thereafter NNC0195-0092 (somapacitan) (0.16 mg/kg/week) during the long-term safety extension periods.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somapacitan</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) once-weekly.</description>
    <arm_group_label>Blinded NNC0195-0092 (somapacitan) (0.04 mg/kg/week)</arm_group_label>
    <arm_group_label>Blinded NNC0195-0092 (somapacitan) (0.08 mg/kg/week)</arm_group_label>
    <arm_group_label>Blinded NNC0195-0092 (somapacitan) (0.16 mg/kg/week)</arm_group_label>
    <arm_group_label>Open labelled daily Norditropin® (0.034 mg/kg/day)</arm_group_label>
    <other_name>NNC0195-0092</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norditropin® FlexPro® pen</intervention_name>
    <description>Administered subcutaneously (s.c., under the skin) once daily.</description>
    <arm_group_label>Open labelled daily Norditropin® (0.034 mg/kg/day)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Cohort I:

          -  Boys: Tanner stage 1 for pubic hair and testis volume below 4 ml , age at least 2
             years and 26 weeks and below or equal to 10.0 years at screening

          -  Girls: Tanner stage 1 for breast development (no palpable glandular breast tissue) and
             pubic hair, age at least 2 years and 26 weeks and below or equal to 9.0 years at
             screening

          -  Confirmed diagnosis of GHD (growth hormone deficiency) within 12 months prior to
             screening as determined by two different GH (growth hormone) stimulation tests,
             defined as a peak GH level of below or equal to 7.0 ng/ml. For children with three or
             more pituitary hormone deficiencies only one GH stimulation test is needed

          -  No prior exposure to GH therapy and/or IGF-I (insulin-like growth factor I) treatment

          -  Height of at least 2.0 standard deviations below the mean height for chronological age
             (CA) and gender according to the standards of Centers for Disease Control and
             Prevention 2-20 years: Girls/Boys stature-for-age and weight-for-age percentiles CDC
             at screening

          -  Annualized height velocity (HV) below the 25th percentile for CA (chronological age)
             and gender or below -0.7 SD (standard deviation) score for CA and sex, according to
             the standards of Prader calculated over a time span of minimum 6 months and maximum 18
             months

        Cohort II:

          -  Below 2 years and 26 weeks and a minimum weight of 5 kg at screening.

          -  Confirmed diagnosis of GHD, the GHD diagnosis must be confirmed by investigator
             according to local practice.

          -  For GH treatment naïve subjects, no prior exposure to GH therapy and/or IGF-I
             treatment.

          -  For GH treatment naïve subjects, IGF-1 SDS below -1.0 at screening, compared to age
             and sex normalized range according to central laboratory measurements.

        Cohort III:

        Age:

          -  Girls: Above 9 years and below or equal to 17 years at screening.

          -  Boys: Above 10 years and below or equal to 17 years at screening.

          -  Confirmed diagnosis of GHD

               1. for GH treatment naïve subjects, confirmed diagnosis within 12 months prior to
                  screening as determined by two different GH stimulation tests, defined as a peak
                  GH level of equal to or below 7.0 ng/ml. For children with three or more
                  pituitary hormone deficiencies only one GH stimulation test is needed. FOR JAPAN
                  ONLY: Confirmed diagnosis of GHD within 12 months prior to screening as
                  determined by one GH stimulation tests for patients with intracranial organic
                  disease or symptomatic hypoglycaemia and two different GH stimulation test for
                  other patients, defined as a peak GH level of equal to or below 6 ng/ml by assay
                  using recombinant GH standard.

               2. for non-GH treatment naïve subjects, confirmed GHD diagnosis by investigator
                  according to local practice

          -  For GH treatment naïve subjects, no prior exposure to GH therapy and/or IGF-I
             treatment.

          -  Open epiphyses; defined as bone age below 14 years for females and bone age below 16
             years for males.

        Exclusion Criteria:

          -  Any clinically significant abnormality likely to affect growth or the ability to
             evaluate

          -  growth with standing/length measurements: Chromosomal aneuploidy and significant gene
             mutations causing medical &quot;syndromes&quot; with short stature, including but not limited to
             Turner syndrome, Laron syndrome, Noonan syndrome, or absence of GH receptors.
             Congenital abnormalities (causing skeletal abnormalities), including but not limited
             to Russell-Silver Syndrome, skeletal dysplasias. Significant spinal abnormalities
             including but not limited to scoliosis, kyphosis and spina bifida variants

          -  Children born small for gestational age (SGA - birth weight and/or birth length
             below-2 SD for gestational age)

          -  Concomitant administration of other treatments that may have an effect on growth (not
             applicable to non-GH treatment naïve subjects in cohort II and III), including but not
             limited to methylphenidate for treatment of attention deficit hyperactivity disorder
             (ADHD)

          -  Prior history or presence of malignancy and/or intracranial tumour
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Reporting Anchor and Disclosure (1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novo Nordisk</last_name>
    <phone>(+1) 866-867-7178</phone>
    <email>clinicaltrials@novonordisk.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Centennial</city>
        <state>Colorado</state>
        <zip>80112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55454</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <zip>11501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Linz</city>
        <zip>4020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Salzburg</city>
        <zip>A 5020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>St. Poelten</city>
        <zip>A 3100</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Villach</city>
        <zip>9500</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Vöcklabruck</city>
        <zip>A 4840</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4030</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>Sao Paulo</state>
        <zip>01228-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>ANGERS cedex 09</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Toulouse cedex 9</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kochi</city>
        <state>Kerala</state>
        <zip>682041</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411001</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>New Dehli</city>
        <state>New Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Beer Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kfar Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49202</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kanagawa</city>
        <zip>216-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>553-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Osaka</city>
        <zip>594-1101</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8519</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Tokyo</city>
        <zip>157 8535</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ljubljana</city>
        <zip>1525</zip>
        <country>Slovenia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Umeå</city>
        <zip>901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34890</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Slovenia</country>
    <country>Sweden</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 25, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism, Pituitary</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

